SGLT2 inhibitors’ interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn-Reference-Cited by-同舟云学术

SGLT2 inhibitors’ interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn

Published:2019-08 Issue:2 Volume:96 Page:283-286
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

van Baar Michaël J.B.,Scholtes Rosalie A.,van Raalte Daniël H.

Publisher

Elsevier BV

Subject

Nephrology

Reference9 articles.

1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

2. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes;Parving;N Engl J Med,2001

3. Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics;Mayer;Kidney Int,2019

4. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus;Cherney;Circulation,2014

5. Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial;Bakris;J Am Soc Nephrol,1995

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering the kidney hemodynamic effects of SGLT2 inhibition: translating insights from rats to humans in type 2 diabetes;Kidney International;2024-09

2. New Insights into the Nephroprotective Potential of Lercanidipine;International Journal of Molecular Sciences;2023-09-13

3. The Association of Background Medications on Initial eGFR Change and Kidney Outcomes in Diabetic Patients Receiving SGLT2 Inhibitor;Clinical Journal of the American Society of Nephrology;2023-03-31

4. Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors;Nephrology;2021-01-04

5. Sodium-glucose co-transporter-2 inhibitors: peculiar “hybrid” diuretics that protect from target organ damage and cardiovascular events;Nutrition, Metabolism and Cardiovascular Diseases;2020-09